Results of the phase III AFFIRM trial shows that enzalutamide (MDV3100) significantly prolonged survival of men with metastatic castration-resistant prostate cancer after chemotherapy
A new oral treatment is showing promise in relapsed, refractory colorectal cancer. Patients given TAS-102, an antitumor agent, showed improved survival and reduced risk of death compared to those given a placebo.
A new study provides evidence that individuals whose pancreas was exposed to radiation during treatment of their childhood cancer have a higher risk of developing diabetes.
Researchers in Germany have found that longer-term follow-up would still lower risk of colorectal cancer development among patients who had an adenoma detected and removed.
The oral selective MEK inhibitor trametinib improved progression-free and overall survival over chemotherapy in patients with metastatic melanoma with a BRAF mutation, according to a new phase III trial.
Sentinel lymph node biopsy is recommended for patients with newly diagnosed intermediate-thickness melanomas, while the procedure may not be indicated for patients with thinner lesions, according to a new set of guidelines.
Researchers have found that tumors with multiple cancer genomes and the downregulation of the LRP1B gene are associated with chemotherapy resistance among patients with the high-grade serous ovarian cancer.
A new study provides evidence that older women with early-stage breast cancer who undergo radiation therapy following a lumpectomy are less likely to require a subsequent mastectomy.
A common genetic mutation in BIM appears to play a role in resistance to tyrosine kinase inhibitors in chronic myeloid leukemia (CML) and EGFR-mutated NSCLC.
Ariad Pharmaceuticals has asked the FDA for an accelerated approval of the BCR-ABL inhibitor ponatinib, based on promising data from ongoing phase II trials.